Until recently, the focus of our research in the noninvasive diagnosis of Down syndrome was the genetic analysis of intact fetal nucleated erythrocytes from the circulation of pregnant women (1 ). The initial step in the physical isolation of these target cells involves the layering of diluted maternal blood on a density gradient (2 ). Before 1997, we routinely discarded the plasma layer of the density gradient, unaware of the fact that it could contain nucleic acids. In 1997, prompted by reports of large quantities of tumor-specific DNA sequences in the plasma and serum of cancer patients (3-5 ), Lo et al. (6 ) demonstrated the presence of male fetal DNA sequences in the serum and plasma of pregnant women. Subsequently, this same group extended their observations by quantifying the fetal DNA in maternal plasma (7 ) and studying its kinetics and physiology (8 ).
Until recently, the focus of our research in the noninvasive diagnosis of Down syndrome was the genetic analysis of intact fetal nucleated erythrocytes from the circulation of pregnant women (1 ) . The initial step in the physical isolation of these target cells involves the layering of diluted maternal blood on a density gradient (2 ) . Before 1997, we routinely discarded the plasma layer of the density gradient, unaware of the fact that it could contain nucleic acids. In 1997, prompted by reports of large quantities of tumor-specific DNA sequences in the plasma and serum of cancer patients (3) (4) (5) , Lo et al. (6 ) demonstrated the presence of male fetal DNA sequences in the serum and plasma of pregnant women. Subsequently, this same group extended their observations by quantifying the fetal DNA in maternal plasma (7 ) and studying its kinetics and physiology (8 ) .
The detection and/or quantification of fetal DNA sequences in maternal plasma have been used for a variety of clinical applications, including diagnosis of gender, Rhesus D genotype, single gene disorders, aneuploidy, and preeclampsia [reviewed in Refs. (9, 10 ) ]. More recently, it has also been suggested that the genetic material in the plasma consists of a continuum of intact and apoptotic cells as well as cell-free DNA (11, 12 ) . Fetal DNA, however, appears to exist predominantly in a cell-free form in the maternal plasma (13 ) . Despite advances in the clinical applications of this technology, to date not much is known about the tissue of origin of the cell-free fetal DNA and how it is metabolized in the pregnant woman. Botezatu et al. (14 ) demonstrated that male DNA sequences could be found in the urine of women who received a blood transfusion from a male donor, as well as women who were pregnant with a male fetus. The mechanism of DNA transfer across the kidney was unknown. Other groups have not yet replicated these findings in the literature.
To understand the metabolism of fetal DNA in the mother, we decided to examine amniotic fluid because at 16 -20 weeks of gestation it is in transition from being identical to fetal plasma to being composed of fetal urine (15 ) . We hypothesized that demonstration of the existence of cell-free fetal DNA in amniotic fluid might provide a clue to the tissue source of DNA in the maternal plasma, as well as lead to novel clinical applications.
This study was performed with approval from the hospital's Institutional Review Board. Thirty-eight coded frozen discarded amniotic fluid specimens were obtained from the Cytogenetics Laboratory. All samples were collected for routine indications, such as advanced maternal age, abnormal maternal serum screening results, or detection of a fetal sonographic abnormality. The standard protocol in the Cytogenetics Laboratory is, upon receipt, to centrifuge the amniotic fluid sample at 350g for 10 min in a bench-top centrifuge, place the cell pellet in tissue culture, assay an aliquot of the fluid for ␣-fetoprotein and acetyl cholinesterase, and store the remainder at Ϫ20°C as a back-up in case of assay failure. After 6 months, the frozen amniotic fluid supernatant samples usually are discarded. Results of the fetal karyotype were revealed only after the study was completed.
The frozen amniotic fluid samples were initially thawed at 37°C and then vortex-mixed for 15 s. An aliquot of 500 L of fluid was centrifuged at 13 500g in a microcentrifuge to remove any remaining cells. A final volume of 400 L of the supernatant was used for extraction of DNA. Extraction was performed with the QIAamp Blood Kit (Qiagen) using the "Blood and Body Fluid" protocol as described by the manufacturer. The DNA was eluted into a final volume of 100 L. Aerosol-resistant tips were used throughout the protocol to prevent contamination with exogenous DNA.
Real-time quantitative PCR analysis was performed using a Perkin-Elmer Applied Biosystems (PE-ABI) 7700 Sequence Detector. Analysis was based on the 5Ј-to-3Ј exonuclease Clinical Chemistry 47, No. 10, 2001 activity of the Taq DNA polymerase, using the FCY locus as a basis for detecting male DNA if the fetus was male. The FCY primers were derived from the Y-chromosome-specific sequence, Y49a (DYS1) (16 ) . The FCY amplification system consisted of the amplification primers FCY-F (5Ј-TCCTGCT-TATCCAAATTCACCAT-3Ј), FCY-R (5Ј-ACTTCCCTCT-GACATTACCTGATAATTG-3Ј), and a dual-labeled fluorescent TaqMan probe FCY-T (5Ј-FAM-AAGTCGCCACTG-GATATCAGTTCCCTTGT-TAMRA-3Ј). The ␤-globin gene was used to confirm the presence of DNA and estimate its overall concentration.
Amplification reactions were set up as described previously by Lo et al. (7 ) , except that each primer was used at 100 nmol/L and the probe was used at 50 nmol/L. Amplification data were collected by the 7700 Sequence Detector and analyzed using the Sequence Detection System software, Ver. 1.6.3 (PE-ABI). Each sample was run in quadruplicate with the mean results of the four reactions used for further calculations. An amplification calibration curve was created using titrated purified male DNA. The extractions and subsequent quantitative assays were performed twice for each sample, with the mean of the two results used for final analysis.
The mean gestational age of the pregnancies in which the fluids were obtained was 16 weeks, 6 days (range, 14 weeks, 3 days to 20 weeks). In one sample, the gestational age was not recorded. In 21 samples, the fetal karyotype was 46,XX; in 15 samples, the karyotype was 46,XY; and in 2 samples, the karyotype was 47,XY,ϩ21. The actual amounts of total and fetal DNA detected in the 38 samples are shown in Table 1 . The mean amount of ␤-globin DNA detected was 3427 genome-equivalents (GE)/mL (range, 293-15 786 GE/mL). There was no correlation between gestational age and the total amount of DNA detected. In the female fetuses, 0 GE/mL of Y DNA was detected in the amniotic fluid. The mean amount of male DNA detected in male fetuses was 2668 GE/mL (range, 228 -12 663 GE/mL). Linear regression analysis showed a correlation between fetal DNA and gestational age (r ϭ 0.6225; P ϭ 0.0231). In all 38 cases, the predicted fetal gender was correct. These results are statistically significant (P Ͻ0.0001, Fisher's exact test). In the two cases of fetal Down syndrome, there was no increase in the amount of fetal DNA compared with the karyotypically normal male fetuses. Amniotic fluid is obtained via an invasive procedure, but it represents another source of material for the study of cell-free fetal DNA production and clearance. We have demonstrated the presence of large quantities of cell-free fetal DNA in stored amniotic fluid supernatant samples. There is ϳ100-to 200-fold more fetal DNA per milliliter of amniotic fluid compared with maternal plasma (7 ). This higher amount may permit new studies and clinical applications to be performed on this typically discarded material.
Although gender prediction was 100% correct, there was no evidence of increased fetal DNA in the two fetuses with trisomy 21. We previously hypothesized that mothers carrying fetuses with Down syndrome have increased amounts of fetal DNA in their plasma because of placental abnormality (17 ) . If the source of fetal DNA in the amniotic fluid were placental, one would expect to observe more fetal DNA in amniotic fluid from Down syndrome pregnancies. This suggests that either our original hypothesis was incorrect or that the source of fetal DNA in the amniotic fluid is not placental.
In some cases, there was a discrepancy between the amounts of fetal and total DNA detected. A possible explanation for the detection of more copies of FCY than ␤-globin sequence per milliliter is that some men may have more than one copy of FCY present in their genome. The fact that, in a few cases, more ␤-globin than FCY sequences were detected was unexpected. At the present time, however, we think it is unlikely that significant amounts of maternal cell-free DNA are present in the amniotic fluid. The fetal DNA in the amniotic fluid is either excreted by the fetal kidneys, locally degraded, or permeates through the nonkeratinized fetal skin. If excreted, it may be that the relatively immature fetal kidney (at 16 -18 weeks) functions differently than the adult pregnant female kidney. If it originates from local degradation, potential sources of apoptosis and DNA liberation include the fetal kidney, blood cells, and direct degradation of placenta or membranes, skin, or other organs undergoing apoptosis with direct contact with the amniotic fluid. One example is the lung, which is actively developing and remodeling during the second trimester, and fetal lung fluid is in direct contact with amniotic fluid.
Although the present study adds another piece to the puzzle, our findings do not solve the mystery of how the pregnant woman clears the fetal DNA from her circulation. In fact, it raises more questions, such as how the fetus eliminates the DNA from its amniotic cavity. Does the free DNA cross the placenta, or is it swallowed and degraded in the fetal intestines? Future studies will attempt to identify the specific tissue of origin of the fetal DNA in amniotic fluid and track its metabolism and/or transfer into the circulation of the pregnant woman.
